The Journal of Immunology, Vol 144, Issue 5 1640-1645, Copyright © 1990 by American Association of Immunologists

ARTICLES

Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration

GC Tsokos, JD Lambris, FD Finkelman, ED Anastassiou and CH June
Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.

We have performed experiments to investigate the role of ligands for complement receptor 2 (CR2) in human B cell activation. Flow microfluorimetry was used to assess changes in free intracytoplasmic calcium concentration [Ca2+] in indo-loaded B cells, immediately after exposure to anti-mu antibody and to monovalent or polyvalent CR2 ligands. As monovalent ligands we used the C3d fragment and synthetic C3 peptides (peptides P14, residues 1201-1214, and P28, residues 1187- 1214). As polyvalent ligands we used i) an intact monoclonal mouse anti- CR2 antibody (HB5) and its F(ab')2 fragment, ii) tetravalent P13 [residues 1202-1214) 4-template), and iii) P28 conjugated to BSA (molar ratio 5/1). Anti-CR2 antibody HB5, tetravalent P13, and P28 conjugated to BSA, enhanced the ability of F(ab')2 fragments of the IgG fraction of goat anti-human mu antibody to increase human B cell [Ca2+]i. In contrast, the monomeric CR2 ligands C3d and P28 inhibited the anti-mu- induced increase in human B cell [Ca2+]i. Multivalent P13, P28, and the HB5, by themselves, did not affect B cell [Ca2+]i. These experiments suggest that the valence of the CR2 ligands is crucial for the nature (synergistic vs antagonistic) of the message transmitted through the CR2.

This article has been cited by other articles:

				Y. Lee, K. M. Haas, D. O. Gor, X. Ding, D. R. Karp, N. S. Greenspan, J. C. Poe, and T. F. Tedder Complement Component C3d-Antigen Complexes Can Either Augment or Inhibit B Lymphocyte Activation and Humoral Immunity in Mice Depending on the Degree of CD21/CD19 Complex Engagement J. Immunol., December 15, 2005; 175(12): 8011 - 8023. [Abstract] [Full Text] [PDF]

				E. S. Bergmann-Leitner, S. Scheiblhofer, R. Weiss, E. H. Duncan, W. W. Leitner, D. Chen, E. Angov, F. Khan, J. L. Williams, D. B. Winter, et al. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria Int. Immunol., March 1, 2005; 17(3): 245 - 255. [Abstract] [Full Text] [PDF]

				S. T. Test, J. K. Mitsuyoshi, and Y. Hu Depletion of Complement Has Distinct Effects on the Primary and Secondary Antibody Responses to a Conjugate of Pneumococcal Serotype 14 Capsular Polysaccharide and a T-Cell-Dependent Protein Carrier Infect. Immun., January 1, 2005; 73(1): 277 - 286. [Abstract] [Full Text] [PDF]

				D. Morikis and J. D. Lambris The Electrostatic Nature of C3d-Complement Receptor 2 Association J. Immunol., June 15, 2004; 172(12): 7537 - 7547. [Abstract] [Full Text] [PDF]

				S. Han, E. Marinova, and B. Zheng Rectification of age-related impairment in Ig gene hypermutation during a memory response Int. Immunol., April 1, 2004; 16(4): 525 - 532. [Abstract] [Full Text] [PDF]

				M. Suresh, H. Molina, M. S. Salvato, D. Mastellos, J. D. Lambris, and M. Sandor Complement Component 3 Is Required for Optimal Expansion of CD8 T Cells During a Systemic Viral Infection J. Immunol., January 15, 2003; 170(2): 788 - 794. [Abstract] [Full Text] [PDF]

				S. D. Fleming, T. Shea-Donohue, J. M. Guthridge, L. Kulik, T. J. Waldschmidt, M. G. Gipson, G. C. Tsokos, and V. M. Holers Mice Deficient in Complement Receptors 1 and 2 Lack a Tissue Injury-Inducing Subset of the Natural Antibody Repertoire J. Immunol., August 15, 2002; 169(4): 2126 - 2133. [Abstract] [Full Text] [PDF]

				C. H. Nielsen and R. G. Q. Leslie Complement's participation in acquired immunity J. Leukoc. Biol., August 1, 2002; 72(2): 249 - 261. [Abstract] [Full Text] [PDF]

				M. Jozsi, J. Prechl, Z. Bajtay, and A. Erdei Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes J. Immunol., March 15, 2002; 168(6): 2782 - 2788. [Abstract] [Full Text] [PDF]

				L. Chakravarty, M. D. Zabel, J. J. Weis, and J. H. Weis Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation Int. Immunol., February 1, 2002; 14(2): 139 - 146. [Abstract] [Full Text] [PDF]

				M. R. Sarrias, S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220 J. Immunol., August 1, 2001; 167(3): 1490 - 1499. [Abstract] [Full Text] [PDF]

				L. A. Vereshchagina, M. Tolnay, and G. C. Tsokos Multiple Transcription Factors Regulate the Inducible Expression of the Human Complement Receptor 2 Promoter J. Immunol., May 15, 2001; 166(10): 6156 - 6163. [Abstract] [Full Text] [PDF]

				S. T. Test, J. Mitsuyoshi, C. C. Connolly, and A. H. Lucas Increased Immunogenicity and Induction of Class Switching by Conjugation of Complement C3d to Pneumococcal Serotype 14 Capsular Polysaccharide Infect. Immun., May 1, 2001; 69(5): 3031 - 3040. [Abstract] [Full Text] [PDF]

				D. Qin, J. Wu, M. C. Carroll, G. F. Burton, A. K. Szakal, and J. G. Tew Evidence for an Important Interaction Between a Complement-Derived CD21 Ligand on Follicular Dendritic Cells and CD21 on B Cells in the Initiation of IgG Responses J. Immunol., November 1, 1998; 161(9): 4549 - 4554. [Abstract] [Full Text] [PDF]